RxDoctor Payments Data

Matthew McKeever, MD

Radiation Oncology · Fort Smith, ARNPI 1891145538

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 245 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,341 and has fallen 89.5% since, to $141 in 2025. Among radiation oncology clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,721in general payments, 2019–2025

Across 245 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$758
  • Merck$342
  • AstraZeneca$341
  • Eisai Inc.$298
  • Seagen Inc.$227
  • Novocure Inc.$217
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$4,69799%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,721 in reported general payments places this provider in the 95th percentile of 45 radiation oncology providers in Arkansas.

See all radiation oncology providers in Arkansas

Medicare billing

Part B allowed, 2024
$240,395
Medicare patients
345
Services billed
2,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mometasone Furoate32$814
Oxycodone Hcl19$485
Nystatin17$362
Tamsulosin Hcl16$270
Gabapentin17$211
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen20$174
Memantine Hcl12$123

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →